Lesson
Classification, Hemodynamics, and Vascular Biology
Pulmonary hypertension describes elevated pulmonary pressure. PAH is the Group 1 precapillary phenotype after other causes of precapillary pulmonary hypertension have been excluded.
- Five clinical groups
- mPAP, PAWP, and PVR
- Precapillary versus postcapillary
- Pulmonary vascular remodeling
- Right ventricular afterload
Confirms pulmonary hypertension by right-heart catheterization
Supports a precapillary rather than left-sided filling pattern
Shows a pathologic pressure cost for each unit of pulmonary flow
Start with the five-group framework
Group 1 is PAH. Group 2 reflects left-heart disease. Group 3 reflects lung disease or hypoxia. Group 4 is pulmonary artery obstruction, most importantly chronic thromboembolic pulmonary hypertension. Group 5 contains unclear or multifactorial mechanisms. Similar pressure values can therefore require fundamentally different treatment.
Read the invasive pattern
Pulmonary hypertension is resting mean pulmonary artery pressure above 20 mmHg by right-heart catheterization. Precapillary pulmonary hypertension adds pulmonary artery wedge pressure at or below 15 mmHg and pulmonary vascular resistance above 2 Wood units. Postcapillary disease has wedge pressure above 15 mmHg, with resistance used to separate isolated from combined postcapillary physiology.
Calculate resistance before interpreting it
PVR equals mean pulmonary artery pressure minus wedge pressure, divided by cardiac output. A mean pressure of 42 mmHg, wedge pressure of 10 mmHg, and output of 4 L per minute gives 8 Wood units. Check waveform quality, zero level, respiratory phase, volume status, and output method before trusting a single value.
Connect remodeling to right-heart failure
Endothelial dysfunction, vasoconstriction, inflammation, in situ thrombosis, smooth-muscle and fibroblast proliferation, and imbalanced BMPR2 and activin signaling narrow the pulmonary vascular bed. Rising resistance increases right ventricular wall stress, oxygen demand, dilation, tricuspid regurgitation, interventricular dependence, and eventually systemic congestion and low output.
Quick check
Checking for saved practice…
Lesson
Detection, Confirmation, and Phenotyping
The diagnostic sequence moves from clinical suspicion to echocardiographic probability, then to expert-center confirmation and etiologic classification.
- Clinical suspicion
- Echocardiographic probability
- Right-heart catheterization
- V/Q screening for CTEPH
- Cause and phenotype
Dyspnea, syncope, right-heart findings, or a high-risk condition
Velocity plus right-heart, septal, arterial, and venous signs
Pressure, wedge, output, resistance, saturation, and cause
Recognize the clinical signal
Progressive exertional dyspnea, fatigue, chest pressure, presyncope, syncope, reduced exercise tolerance, edema, ascites, a loud pulmonary component of S2, right ventricular heave, elevated jugular venous pressure, and tricuspid regurgitation can suggest pulmonary hypertension. Syncope, low output, hypotension, or rapidly progressive symptoms demand urgent expert referral.
Use echocardiography to estimate probability
Tricuspid regurgitation velocity plus right-heart size, septal shape, pulmonary artery findings, venous dimensions, and right ventricular function estimate probability. Echocardiography can reveal left-heart or valve disease, but its pressure estimate neither proves pulmonary hypertension nor replaces invasive classification.
Confirm with a complete catheterization
Measure right atrial, right ventricular, pulmonary artery, and wedge pressures, oxygen saturation, and cardiac output. Calculate PVR and assess shunt when indicated. Fluid or exercise challenge can clarify occult left-heart physiology in selected cases. Acute vasoreactivity testing is reserved for selected idiopathic, heritable, or drug-associated PAH.
Find the cause before choosing the drug
Review ECG, chest imaging, pulmonary function, arterial oxygenation, ventilation-perfusion imaging, laboratory testing, connective-tissue disease, HIV, portal hypertension, congenital heart disease, drugs and toxins, family history, and genetics. A normal CT angiogram does not replace ventilation-perfusion screening when chronic thromboembolic disease remains possible.
Quick check
Checking for saved practice…
Lesson
Right Ventricular Function, Risk, and Supportive Care
Risk is multidimensional and dynamic. Treatment aims to move the patient toward a low-risk profile while preserving right ventricular function and daily life.
- WHO functional class
- Exercise capacity
- BNP and NT-proBNP
- Imaging and hemodynamics
- Congestion and supportive care
Symptoms and exercise reveal daily reserve
Myocardial strain adds biologic trajectory
Imaging and output show compensation or failure
Measure more than pressure
WHO functional class, six-minute walk distance, BNP or NT-proBNP, echocardiographic or cardiac magnetic resonance right ventricular findings, right atrial pressure, cardiac index, mixed venous oxygen saturation, symptoms, and clinical trajectory provide complementary information. A high pulmonary pressure alone does not define the right ventricle's reserve.
Use risk at baseline and follow-up
At diagnosis, a multiparameter three-strata approach informs initial intensity. During follow-up, a four-strata framework separates low, intermediate-low, intermediate-high, and high risk. The goal is a low-risk state, not merely stable symptoms. Failure to improve should trigger implementation review and treatment escalation.
Protect preload without accepting congestion
Loop diuretics and selected adjuncts relieve edema, ascites, and hepatic congestion, but excessive volume removal can reduce right ventricular preload and systemic output. Track weight, symptoms, blood pressure, renal function, sodium, potassium, magnesium, and diuretic response. Oxygen treats documented hypoxemia rather than pulmonary pressure by itself.
Build supportive care around function
Supervised exercise and rehabilitation are appropriate when clinically stable. Vaccination, iron evaluation, contraception and pregnancy counseling, psychosocial support, travel and altitude planning, oxygen logistics, adherence, and palliative symptom care belong in the treatment plan. Anticoagulation is individualized rather than routine for every PAH patient.
Quick check
Checking for saved practice…
Lesson
Conventional Therapy and Patient-Centered Care
Supportive care treats congestion, hypoxemia, functional loss, iron deficiency, and preventable risk while preserving the preload and perfusion needed by the right ventricle.
- Volume and oxygen strategy
- Exercise and prevention
- Anticoagulation decisions
- Adherence and access
- Follow-up and self-management
Relieve congestion while preserving preload, pressure, kidney function, and output
Correct hypoxemia and use supervised activity when clinically stable
Coordinate access, prevention, travel, adherence, support, and follow-up
Relieve congestion without collapsing preload
Diuretics are used for edema, ascites, hepatic congestion, and rapid weight gain. Dose and combination choices follow symptoms, examination, urine response, blood pressure, kidney function, sodium, potassium, and magnesium. The target is euvolemia. Excessive removal can reduce right ventricular filling, systemic pressure, and cardiac output.
Use oxygen and exercise for the right reason
Supplemental oxygen treats documented hypoxemia rather than pulmonary vascular resistance by itself. Stable patients benefit from supervised exercise or rehabilitation after treatment has been optimized. New syncope, hypotension, chest pain, or decompensation requires reassessment before exercise is advanced.
Individualize anticoagulation and prevention
Anticoagulation is not automatic for every PAH phenotype. A separate indication, disease subtype, thrombosis history, catheter status, bleeding risk, drug interaction, and patient preference guide the decision. Vaccination, iron evaluation, smoking avoidance, contraception counseling, travel planning, and infection prevention reduce avoidable stress on limited right-heart reserve.
Design care that can survive daily life
Adherence depends on access, refill timing, treatment burden, pump supplies, storage, travel, health literacy, support, and rapid access to an expert team. Follow-up reviews symptoms, weight, functional class, exercise capacity, biomarkers, imaging, hemodynamics when needed, adverse effects, and the complete medication implementation process.
Quick check
Checking for saved practice…
Lesson
Targeted Pathways and Clinical Pharmacology
PAH pharmacology addresses deficient nitric oxide and prostacyclin signaling, excess endothelin signaling, and abnormal activin-family signaling through distinct molecular strategies.
- PDE5 inhibition and sGC stimulation
- Endothelin receptor antagonism
- Prostacyclin analogues and IP agonism
- Activin signaling inhibition
- Routes, interactions, and monitoring
Increase cyclic signaling through PDE5, sGC, or IP pathways
Reduce a potent vasoconstrictive and proliferative signal
Sotatercept modifies a remodeling pathway beyond vasodilation
Increase cyclic GMP through one nitric oxide strategy
Sildenafil and tadalafil inhibit PDE5 and preserve cyclic GMP. Riociguat directly stimulates soluble guanylate cyclase and also sensitizes it to nitric oxide. Nitrates are contraindicated with PDE5 inhibitors because profound hypotension can occur. PDE5 inhibitors and riociguat should not be combined. Review pressure, interacting CYP drugs, organ function, and visual or hearing symptoms.
Block endothelin signaling
Bosentan blocks ETA and ETB receptors, while ambrisentan is relatively ETA selective and macitentan provides dual antagonism. Class concerns include embryo-fetal toxicity, edema, anemia, and potential hepatic effects. Current product-specific labeling determines pregnancy testing, contraception, liver and hemoglobin monitoring, interactions, and dispensing requirements. Bosentan has substantial CYP interactions.
Restore prostacyclin pathway activity
Epoprostenol is continuous intravenous therapy with a very short half-life. Treprostinil has intravenous, subcutaneous, inhaled, and oral products with formulation-specific use. Iloprost is inhaled. Selexipag is an oral selective IP receptor agonist with an active metabolite. Headache, flushing, jaw pain, diarrhea, nausea, hypotension, and site or catheter complications require anticipatory counseling. Abrupt interruption of parenteral prostacyclin can cause rapid deterioration.
Modify proliferative signaling with sotatercept
Sotatercept-csrk is an ActRIIA-Fc ligand trap that rebalances activin-family signaling. Current US labeling uses subcutaneous dosing every three weeks, beginning at 0.3 mg per kg and targeting 0.7 mg per kg in eligible adults on background therapy. Monitor hemoglobin and platelets before early doses and periodically. Erythrocytosis, thrombocytopenia, serious bleeding, embryo-fetal toxicity, telangiectasia, fertility concerns, and administration technique shape safe use.
Quick check
Checking for saved practice…
Lesson
Dosing, Delivery, Interactions, and Monitoring
PAH safety depends as much on route, titration, interaction control, laboratory surveillance, and continuity as it does on choosing the correct molecular pathway.
- Oral dose and interaction review
- Inhaled technique
- Parenteral continuity
- Laboratory surveillance
- Medication reconciliation
Check incompatible pathways, metabolism, organ function, and missed-dose rules
Teach preparation, technique, maintenance, and formulation-specific use
Protect access, pumps, supplies, sterility, and immediate backup during interruption
Keep pathway combinations pharmacologically coherent
Nitrates cannot be combined with PDE5 inhibitors, and riociguat cannot be combined with a PDE5 inhibitor. Smoking changes can alter riociguat exposure. Strong metabolic inhibitors or inducers can change exposure to bosentan, macitentan, sildenafil, tadalafil, selexipag, and other agents. Product-specific renal and hepatic restrictions must be checked at every transition.
Match teaching to the delivery system
Inhaled products require device-specific preparation, technique, maintenance, and missed-dose instructions. Oral treprostinil, inhaled treprostinil, and parenteral treprostinil are not interchangeable by a simple milligram comparison. Selexipag titration is individualized to tolerability, with interaction and interruption rules taken from current labeling.
Treat continuous infusion as a life-sustaining system
Parenteral prostacyclin plans include drug concentration, pump rate, cassette or reservoir preparation, dedicated access, line or site care, backup medication and equipment, emergency contacts, and a response to interruption. Epoprostenol's very short half-life makes unexpected cessation especially dangerous.
Build monitoring around the agent and the patient
Endothelin receptor antagonists require product-specific pregnancy precautions, blood count, edema, liver, and interaction review. Sotatercept requires hemoglobin and platelet monitoring before early doses and periodically, with dose decisions based on current labeling. Every visit should reconcile active ingredient, formulation, dose, route, schedule, access, adverse effects, and clinical response.
Quick check
Checking for saved practice…
Lesson
Risk-Directed Combination Strategy
Initial and follow-up treatment intensity follows mortality risk, cardiopulmonary comorbidity, response, and the ability to deliver complex therapy safely.
- Initial dual oral therapy
- Initial parenteral prostacyclin
- Four-strata follow-up
- Sotatercept add-on
- Transplant referral
ERA plus PDE5 inhibition for many patients without major comorbidity
Bring intravenous or subcutaneous prostacyclin forward
Add pathways, consider sotatercept, and refer for transplant early
Use combination therapy for most low or intermediate-risk patients
For idiopathic, heritable, drug-associated, or connective-tissue-disease PAH without major cardiopulmonary comorbidity, initial ERA plus PDE5 inhibitor therapy is a standard foundation at low or intermediate risk. Monotherapy may be selected for specific phenotypes, contraindications, advanced age with comorbidity, or implementation limits, but the reason should be explicit.
Bring parenteral prostacyclin forward at high risk
High-risk disease or severe right-heart failure generally warrants an initial combination that includes intravenous or subcutaneous prostacyclin, often with ERA and PDE5 inhibitor therapy. This requires expert-center education, pump and line planning, emergency backup, infection prevention, and immediate response to interruption.
Escalate from the follow-up risk state
At follow-up, persistent intermediate-low risk supports pathway escalation, including a prostacyclin-pathway agent, switching a PDE5 inhibitor to riociguat in selected patients, or adding sotatercept under current labeling and expert-center judgment. Intermediate-high or high risk demands parenteral prostacyclin consideration and transplant evaluation rather than serial low-intensity changes.
Audit the entire regimen
Before and after escalation, verify diagnosis, active ingredients, dose and titration, access, adherence, administration, interactions, pregnancy prevention, edema, blood counts, liver and renal status, line or site care, blood pressure, functional response, and risk trajectory. Never stop a PAH therapy abruptly without a coordinated plan.
Quick check
Checking for saved practice…
Lesson
Vasoreactivity, Special Populations, and Decompensation
Several high-consequence phenotypes change the usual PAH plan and require expert-center decisions, precise labeling review, and early escalation.
- Acute vasoreactivity
- Pregnancy and lactation
- PVOD and pulmonary edema
- PAH-associated conditions
- Right-heart decompensation
Only selected positive patients receive high-dose calcium channel blockade
Prevent fetal exposure and recognize vasodilator-associated pulmonary edema
Restore perfusion, treat triggers, and escalate through an expert center
Reserve calcium channel blockers for true responders
Perform acute vasoreactivity testing only in selected idiopathic, heritable, or drug-associated PAH at an expert center. A positive response can support high-dose calcium channel blocker therapy with close reassessment. Empiric calcium channel blockade can cause hypotension, edema, and right-heart deterioration when the required response is absent.
Treat pregnancy as a high-risk state
PAH carries major maternal and fetal risk, so early specialist counseling and highly effective contraception are essential. Endothelin receptor antagonists and sotatercept carry embryo-fetal toxicity warnings. Medication selection during pregnancy and lactation requires current product labeling and a multidisciplinary pulmonary hypertension, maternal-fetal medicine, anesthesia, and critical-care plan. Obsolete pregnancy letter categories should not be used.
Recognize pulmonary veno-occlusive disease
Very low diffusion capacity, marked hypoxemia, septal lines, centrilobular ground-glass change, mediastinal adenopathy, and pulmonary edema after vasodilator treatment can suggest PVOD or pulmonary capillary hemangiomatosis. Vasodilators may provoke pulmonary edema, so expert evaluation and transplant planning are critical.
Stabilize right-heart decompensation and plan ahead
Identify trigger, oxygenation, congestion, perfusion, arrhythmia, infection, anemia, pulmonary embolism, medication interruption, and pregnancy. Preserve systemic pressure and right-coronary perfusion, use cautious diuresis, restore PAH therapy, and employ vasoactive or mechanical support through an experienced center. Recurrent syncope, rising biomarkers, worsening function, low output, or high-risk status should accelerate transplant referral and goals-of-care discussion.
Quick check
Checking for saved practice…
Module practice
Check the connections.
Each attempt draws 10 questions from the complete 120 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Core source material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.